Pfizer to supply 10M courses of COVID drug Paxlovid to developing nations in 2022- Reuters

Mar. 03, 2022 5:56 AM ETPfizer Inc. (PFE)MRKBy: Ravikash, SA News Editor1 Comment

Pfizer (NYSE:PFE) is expected to provide about 10M courses its COVID-19 therapy Paxlovid to low and middle-income nations in 2022, Reuters reported citing Harley Feldbaum, head of strategy for policy at Global Fund, a non-government organization.
The company could increase the supply if agencies involved demonstrate that they are able to distribute the drug, the report added.
Earlier in the week, U.S. President Joe Biden announced the launch of an initiative for Americans to receive free oral therapeutics immediately.
Biden said Pfizer would deliver 1M pills in March and more than double of it in April.
Currently, FDA has approved only two oral COVID-19 drugs for at home use. Pfizer's Paxlovid, and Merck (NYSE:MRK) and Ridgeback Biotherapeutics' molnupiravir.
Earlier in the day, the World Health Organization backed Merck/Ridgeback's pill molnupiravir for certain COVID-19 patients.
In studies, Paxlovid has shown 89% efficacy, and molnupiravir has demonstrated about 30% efficacy in reducing the risk of hospitalization or death in patients with mild-to-moderate COVID-19.
PFE -0.42% premarket to $47.50